Cerebrolysin
PeptideThe medical score (62) is 10 points below the community score (72), as the clinical assessment places greater weight on the industry-sponsored study landscape and lack of independent replication [s3, s9, s10], while community users primarily report subjective effects and give less consideration to anaphylaxis risks or methodological limitations [c1, c4].
Unlock full information
Dosages, side effects, studies and more — free after registration.
Register for freeRating Scales
TL;DR
Cerebrolysin is the most clinically studied peptide on this list: multiple RCTs and meta-analyses show consistent, if moderate, effects in Alzheimer's and vascular dementia, while a 2022 Cochrane review found no clear case for routine use in stroke rehabilitation. The evidence base is predominantly industry-sponsored, which complicates independent assessment. Anaphylaxis is a rare but life-threatening side effect — self-injection without medical supervision is not medically justifiable. In Germany, Cerebrolysin is not regularly available; importing it for personal use sits in a legal grey zone.
Description
Cerebrolysin is an injectable neuropeptide mixture derived from porcine brain tissue with neurotrophic properties, used clinically in stroke, dementia, and TBI [s1, s3].
Cerebrolysin (development name FPF-1070) is a proprietary preparation of enzymatically hydrolyzed, purified porcine brain tissue. It consists of approximately 75% free amino acids and approximately 25% low-molecular-weight neuropeptides (< 10,000 Dalton) capable of crossing the blood-brain barrier [s3, s4]. The preparation contains components resembling Brain-Derived Neurotrophic Factor (BDNF), Nerve Growth Factor (NGF), Glial Cell Line-Derived Neurotrophic Factor (GDNF), and Ciliary Neurotrophic Factor (CNTF) [s1, s3]. Cerebrolysin is administered exclusively parenterally (intravenously or intramuscularly) and is clinically approved in over 50 countries, primarily for stroke rehabilitation, Alzheimer-type dementia, vascular dementia, and traumatic brain injury (TBI) [s2, s5]. In the DACH region, it is approved as a prescription medication in Austria [s1]. Clinical evidence is mixed: several industry-sponsored RCTs demonstrate positive effects on cognitive function and neurological recovery [s6, s7, s8], while Cochrane reviews spanning several decades have failed to establish clear benefit for routine post-stroke use and noted a risk of serious adverse events [s9]. A substantial proportion of the positive evidence base derives from industry-sponsored studies, complicating interpretation [s3, s10]. In the biohacking context, Cerebrolysin is self-injected, which is considered medically risky, as parenteral administration without medical supervision can be dangerous.
Legal Status (DE)
In Austria and several DACH countries, Cerebrolysin® is approved as a prescription medication (manufacturer: EVER Neuro Pharma, Austria) [s1]. In Germany, it is not available through regular pharmacies; use occurs within the framework of medical prescription or clinical trials. In the USA, Cerebrolysin is not FDA-approved and is considered an unapproved drug [s2]. Personal-use importation exists in a legal grey area.
Mechanism of Action
Cerebrolysin acts via multiple simultaneous mechanisms (multimodal) [s3, s4]: 1. Neurotrophic activity: The low-molecular-weight peptides mimic the effects of endogenous neurotrophins such as BDNF and NGF, promoting neuronal survival, stimulating neurogenesis, and supporting synaptic plasticity [s1, s3]. 2. Neuroprotective effects: In animal models, Cerebrolysin reduces excitotoxic damage by inhibiting calpains (calcium-dependent proteases) and attenuates apoptotic cell death [s4]. 3. Metabolic regulation: The preparation improves aerobic energy supply to neurons and reduces lactate acidosis during ischemia [s4]. 4. Neuroplasticity and neurorestoration: In preclinical models, Cerebrolysin promotes axonogenesis, dendritogenesis, and synaptogenesis, contributing to functional recovery after brain injury [s4, s11]. 5. Anti-amyloidogenic effects: In Alzheimer models, reductions in amyloid precursor protein expression and tau hyperphosphorylation have been observed [s3, s4]. The precise composition of the active peptides is proprietary and not fully characterized, which complicates precise mechanistic attribution [s3].
Dosing
Schlaganfall-Rehabilitation (akut)
- Dose
- 30–50 mL Cerebrolysin in 100 mL NaCl 0.9%
- Frequency
- 1× täglich als langsame IV-Infusion über 15–60 Minuten
- Route
- oral
- Duration
- 10–21 Tage
- Timing
- In the acute phase post-stroke under medical supervision
- With food
- vermeiden
Demenz (Alzheimer, vaskulär)
- Dose
- 5–30 mL daily IV or IM
- Frequency
- 1× täglich
- Route
- injektion-intramuskulär
- Duration
- 4 Wochen; ggf. wiederholte Kurse nach 2 Monaten
- Timing
- Course-based administration under medical supervision; repeat until no further improvement
- With food
- vermeiden
Schädel-Hirn-Trauma
- Dose
- 10–30 mL daily IV
- Frequency
- 1× täglich als IV-Infusion
- Route
- oral
- Duration
- 10–20 Tage
- Timing
- During the rehabilitation phase under medical supervision
- With food
- vermeiden
According to the official prescribing information, a maximum of 50 mL per single dose for severe indications; higher doses increase the risk of blood pressure elevation in combination with MAO inhibitors [s12]. Self-injection without medical supervision is not medically recommended.
According to the official prescribing information, Cerebrolysin may only be administered by qualified medical personnel (physician or nursing staff) [s12]. The solution is not miscible with lipid infusions or strongly acidic/alkaline solutions. In the biohacking context, Cerebrolysin is commonly used in cycles of 10–20 days with breaks of 2–3 months [c1, c2].
Calculate reconstitution, plan dosing, look up injection technique
Side Effects
| Side Effect | Frequency | Severity |
|---|---|---|
| Schwindel, Kopfschmerzen, Schwitzen, Übelkeit In controlled clinical trials, these effects occurred at similar frequencies in Cerebrolysin and placebo groups (24% vs. 28% adverse events) [s14]. | gelegentlich | leicht |
| Hautrötung (Flush), Hitzegefühl an der Injektionsstelle Flushing and sensation of heat are among the more commonly reported local reactions with IV administration [s13]. | gelegentlich | leicht |
| Lebensbedrohliche Anaphylaxie A documented case of life-threatening anaphylaxis following Cerebrolysin injection was published in 2024; Cerebrolysin contains porcine brain protein components that can trigger allergic reactions [s13]. | selten | schwer |
| Hypertension (Blutdruckanstieg) bei hohen Dosen + MAO-Hemmer At doses of 30–40 mL Cerebrolysin in combination with high MAO inhibitor doses, a clinically relevant increase in blood pressure may occur [s12]. | selten | moderat |
| Schlaflosigkeit, Agitation Sleep disturbances and restlessness have been reported as adverse effects in isolated studies [s13]. | selten | leicht |
| Krampfanfälle In an RCT on ischemic stroke, 2 patients per group experienced seizures; a causal relationship with Cerebrolysin is not established but cannot be excluded [s14]. | selten | schwer |
Contraindications
The preparation contains porcine protein fragments; allergic reactions including anaphylaxis have been documented [s13].
Free amino acids and peptides may accumulate in impaired renal function; contraindicated according to the summary of product characteristics [s12].
Neurotrophic stimulation may affect the seizure threshold in epileptic patients; caution per summary of product characteristics [s12].
No controlled studies in pregnant women; according to the summary of product characteristics, Cerebrolysin should not be used during pregnancy [s12].
According to the summary of product characteristics, caution is advised in cases of markedly increased autonomic excitability [s12].
Interactions
Synergistic
In stroke treatment studies, Cerebrolysin was safely used in combination with rtPA; the safety profile remained comparable [s15].
In clinical studies, Cerebrolysin was safely combined with cholinesterase inhibitors; no relevant deterioration of the safety profile [s15].
In stroke and brain injury models, Cerebrolysin (BDNF/NGF mimicry, neuroprotection) and BPC-157 (angiogenesis, NO stabilization) act in a complementary manner. The combination may exert a more comprehensive neuroregenerative effect.
Dihexa potentiates the BDNF-TrkB signaling pathway via HGF stabilization, while Cerebrolysin provides natural neurotrophic peptide fragments (BDNF, NGF, CNTF). The combination may create an optimal neurotrophically active milieu.
Alpha-GPC increases acetylcholine availability and supports phosphatidylcholine synthesis. In combination with Cerebrolysin, which provides neurotrophic factors, a complementary enhancement of cognition and synaptic integrity is achieved.
Citicoline increases acetylcholine levels and promotes phosphatidylcholine synthesis in brain cells. Together with Cerebrolysin, which provides neurotrophic peptides, a synergistic enhancement of cognitive function and membrane integrity is plausible.
Cerebrolysin supports neuroprotection and neurotrophic signaling pathways, while ALCAR promotes mitochondrial function and cholinergic neurotransmission. The combination may provide more comprehensive support of cognitive function and cellular energy in the brain.
Bacopa monnieri exerts antioxidant effects on nerve cells, promotes general cellular health in the nervous system, and has a calming effect. In combination with Cerebrolysin, which provides neurotrophic factors, complementary support of memory and neuroprotection is plausible.
Lion's Mane promotes endogenous production of nerve growth factor (NGF), while Cerebrolysin supplies exogenous NGF-like peptide fragments. The combination may produce a synergistic amplification of neurotrophic signaling cascades.
According to clinical reports, MK-677 may improve mitochondrial biogenesis via IGF-1 elevation and reduce headaches that can occur upon Dihexa/Cerebrolysin initiation within 7–10 days. The combination may additionally support cerebral energy supply.
Caution
Additive/synergistic effects possible; antidepressant dose should be reduced in combination therapy. At high Cerebrolysin doses (30–40 mL) + high MAO inhibitor doses: risk of blood pressure increase [s12].
Additive effects on monoaminergic systems described; dose adjustment of the antidepressant recommended [s12].
Studies
Tier A — High Evidence
Outcome: Cognitive function in mild to moderate Alzheimer's dementia (ADAS-Cog, CGI)
Effect Size: SMD -0.40 (95% CI -0.66 to -0.13; p=0.0031) at 4 weeks; not significant at 6 months (SMD -0.37; p=0.171)
Outcome: ADAS-Cog improvement in vascular dementia compared to placebo and other agents
Effect Size: MD -6.20 (95% CI -6.39 to -6.01) vs. placebo
Outcome: Cognitive function in vascular dementia (MMSE, ADAS-Cog)
Effect Size: WMD MMSE +1.10 (95% CI 0.37–1.82)
Outcome: Functional recovery after acute ischemic stroke
Effect Size: Primary outcome (functional recovery day 90) with benefit for Cerebrolysin; see source for details
Tier B — Moderate Evidence
Outcome: Safety and efficacy in early recovery after acute ischemic stroke
Effect Size: 24% AE Cerebrolysin vs. 28% placebo; no significant differences in AE frequency
Outcome: Functional outcome after severe traumatic brain injury
Effect Size: Positive effects on motor and cognitive recovery described; methodological heterogeneity
Tier C — Low Evidence
Outcome: Mechanisms: neuroprotective and neurorestorative effects in animal and cell models
Effect Size: Preclinical positive data on neurogenesis, apoptosis inhibition, amyloid reduction
Community Evidence
Top reported benefits
- Subjectively perceived mental clarity and cognitive enhancement
- Improved mood and emotional stability
- Sensation of faster recovery after exhaustion or brain injury
- Long-lasting effects after injection cycles
Top reported issues
- Fear of injection and improper self-administration
- High cost and procurement difficulties
- Skepticism due to unclear composition (no third-party testing available)
- Uncertainty about placebo effects in subjective reports
Critical users highlight the lack of independent scientific confirmation of positive RCT results and the predominantly industry-sponsored evidence base [c4]. Self-injection without medical supervision is assessed as dangerous by medically informed community members. A 2025 Reddit thread explicitly addressed potential conflicts of interest in Cerebrolysin research [c4].
Scientific Sources
- Cerebrolysin - Wikipedia
Wikipedia contributors (2024). WikipediaCLink - Cerebrolysin Research Evidence and Safety Profile (PeptideInsight)
PeptideInsight editorial team (2024). peptideinsight.comCLink - Effects of cerebrolysin on functional outcome of patients with traumatic brain injury: a systematic review and meta-analysis
Muresanu DF, Heiss WD, Hoemberg V, et al. (2018). CNS & Neurological Disorders - Drug TargetsALink - Cerebrolysin – Zusammenfassung der Merkmale des Arzneimittels (Fachinformation)
EVER Neuro Pharma GmbH (2022). Österreichisches Bundesamt für Sicherheit im Gesundheitswesen (BASG)ALink - Life-Threatening Anaphylaxis due to Cerebrolysin
Trimmel H, Trimmel-Schwahofer P, Chwojka C, et al. (2024). Case Reports in Neurological MedicineCDOI - Efficacy and safety of Cerebrolysin treatment in early recovery after acute ischemic stroke: a randomized, placebo-controlled, double-blinded, multicenter clinical trial
Muresanu DF, Heiss WD, Hoemberg V, et al. (2016). Translational Stroke ResearchALink - Safety profile of Cerebrolysin: clinical experience from dementia and stroke trials
Alvarez XA, Sampedro C, Cacabelos R, et al. (2012). Expert Opinion on Drug SafetyBPMID:22514795DOI - Efficacy of Pharmacotherapies in Improving Cognitive Function in Vascular Dementia: A Network Meta-analysis of Randomized Controlled Trials
Neurology conference authors (2023). Neurology (AAN Annual Meeting abstracts)ADOI - Safety and Efficacy of Cerebrolysin for Neurorecovery After Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of 14 Randomized Controlled Trials
[Vollständige Autorenliste in PMC12465088 — Erstautor nicht aus Suchergebnis extrahierbar] (2025). [Zeitschrift aus PMC-Eintrag — nicht vollständig abrufbar]BLink - Cerebrolysin and repetitive transcranial magnetic stimulation in patients with traumatic brain injury: a three-arm randomised trial
Verisezan Roșu O, Jemna N, Hapca E, Benedek I, Vadan I, Mureșanu I, et al. (2023). Frontiers in NeuroscienceBDOI - Cerebrolysin for stroke, neurodegeneration, and traumatic brain injury: review of the literature and outcomes
Zhang Y, Chopp M, Meng Y, et al. (2021). Journal of NeurosurgeryBPMID:33515100DOI - Cerebrolysin: A Porcine-Derived Neuropeptide Mixture and Its Evidence Profile
Superpower.com editorial team (2024). superpower.comCLink - Cerebrolysin: Neuropeptide Research Overview
PeptideJournal editorial team (2024). peptidejournal.orgCLink - Cerebrolysin approved indications and clinical use (EVER Pharma product information)
EVER Neuro Pharma GmbH (2022). everpharma.comBLink - Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials
Gauthier S, Proaño JV, Jia J, et al. (2015). Dementia and Geriatric Cognitive DisordersAPMID:25832905DOI - Cerebrolysin for vascular dementia
Chen N, Yang M, Guo J, et al. (2013). Cochrane Database of Systematic ReviewsAPMID:23440834DOI - Cerebrolysin for functional recovery in patients with acute ischemic stroke: a meta-analysis of randomized controlled trials
Ghosh R, Roy D, Benito-León J (2017). Journal of the Neurological SciencesAPMID:28458521DOI - Cochrane Review: Cerebrolysin for acute ischaemic stroke (updated 2022)
Ziganshina LE, Abakumova T, Kuchaeva A (2022). Cochrane Database of Systematic ReviewsADOI
Community Sources
Storage
Unopened
Store at room temperature (15–25 °C), protected from light and frost.
Opened
Use opened ampoules immediately; not suitable for reuse.
Notes
Cerebrolysin solution is a clear, slightly yellowish liquid. Do not mix with lipid infusions or strongly acidic or alkaline solutions. Ampoules are single-use preparations [s12].